| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013817356 |
| Molecular Weight (Da) | 442 |
| SMILES | COc1cccc2c(C(=O)N[C@@H]3CC(C)(C)CCC3(C)C)cn(CCN3CCOCC3)c12 |
| Molecular Formula | C26N3O3 |
| Action | Agonist |
| General Information | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013817356 |
| Molecular Weight (Da) | 442 |
| SMILES | COc1cccc2c(C(=O)N[C@@H]3CC(C)(C)CCC3(C)C)cn(CCN3CCOCC3)c12 |
| Molecular Formula | C26N3O3 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013817356 |
| Molar Refractivity | 125.864 |
| HBA | 3 |
| HBD | 1 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 32 |
| LogP | 4.029 |
| Activity (Ki) in nM | 21.878 |
| Polar Surface Area (PSA) | 55.73 |
| Pharmacokinetic Properties | |
|---|---|
| ZINC ID/ Molecule Name | ZINC000013817356 |
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | + |
| Cyp1a2 inhibition | - |
| Oatp2b1 inhibitor | - |
| Oatp1b1 inhibitor | + |
| Oatp1b3 inhibitor | + |
| Mate1 inhibitor | - |
| Oct2 inhibitor | - |
| Bsep inhibitor | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.71788376 |
| Pharmacokinetic Properties | |
|---|---|
| Number of aromatic heavy atoms | 9 |
| Fraction csp3 | 0.65 |
| Ilogp | 4.72 |
| Xlogp3 | 4.32 |
| Wlogp | 3.94 |
| Mlogp | 2.58 |
| Silicos-it log p | 4.19 |
| Consensus log p | 3.95 |
| Esol log s | -5.05 |
| Esol solubility (mg/ml) | 3.98E-03 |
| Esol solubility (mol/l) | 9.00E-06 |
| Esol class | Moderately |
| Ali log s | -5.2 |
| Ali solubility (mg/ml) | 2.76E-03 |
| Ali solubility (mol/l) | 6.25E-06 |
| Ali class | Moderately |
| Silicos-it logsw | -6.43 |
| Silicos-it solubility (mg/ml) | 1.65E-04 |
| Silicos-it solubility (mol/l) | 3.73E-07 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.93 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 4.06 |
| Pharmacokinetic Properties | |
|---|---|
| Logs | -5.68 |
| Logd | 4.474 |
| Logp | 5.337 |
| F (20%) | 0.138 |
| F (30%) | 0.108 |
| Mdck | 1.68E-05 |
| Ppb | 0.8306 |
| Vdss | 1.483 |
| Fu | 0.1236 |
| Cyp1a2-inh | 0.086 |
| Cyp1a2-sub | 0.459 |
| Cyp2c19-inh | 0.77 |
| Cyp2c19-sub | 0.901 |
| Cl | 6.185 |
| T12 | 0.032 |
| H-ht | 0.343 |
| Dili | 0.297 |
| Roa | 0.403 |
| Fdamdd | 0.135 |
| Skinsen | 0.108 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.805 |
| Bcf | 0.907 |
| Igc50 | 3.102 |
| Lc50 | 3.784 |
| Lc50dm | 4.791 |
| Nr-ar | 0.603 |
| Nr-ar-lbd | 0.013 |
| Nr-ahr | 0.046 |
| Nr-aromatase | 0.238 |
| Nr-er | 0.182 |
| Nr-er-lbd | 0.015 |
| Nr-ppar-gamma | 0.013 |
| Sr-are | 0.536 |
| Sr-atad5 | 0.007 |
| Sr-hse | 0.034 |
| Sr-mmp | 0.19 |
| Sr-p53 | 0.026 |
| Vol | 470.205 |
| Dense | 0.939 |
| Flex | 23 |
| Nstereo | 0.304 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 0 |
| Qed | 2 |
| Synth | 0.726 |
| Fsp3 | 3.268 |
| Mce-18 | 0.654 |
| Natural product-likeness | 90.093 |
| Alarm nmr | -0.25 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Rejected |